These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 16433190)
1. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait. Al Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO J Chemother; 2005 Dec; 17(6):607-13. PubMed ID: 16433190 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Samra Z; Ofer O; Shmuely H Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257 [TBL] [Abstract][Full Text] [Related]
3. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. Gemmell CG J Antimicrob Chemother; 2001 Jul; 48(1):47-52. PubMed ID: 11474632 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. Cercenado E; García-Garrote F; Bouza E J Antimicrob Chemother; 2001 Jan; 47(1):77-81. PubMed ID: 11152434 [TBL] [Abstract][Full Text] [Related]
5. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683 [TBL] [Abstract][Full Text] [Related]
6. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS). Ballow CH; Biedenbach DJ; Rossi F; Jones RN; Braz J Infect Dis; 2002 Jun; 6(3):100-9. PubMed ID: 12144745 [TBL] [Abstract][Full Text] [Related]
7. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. Henwood CJ; Livermore DM; Johnson AP; James D; Warner M; Gardiner A J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Draghi DC; Sheehan DJ; Hogan P; Sahm DF Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168 [TBL] [Abstract][Full Text] [Related]
11. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Ross JE; Fritsche TR; Sader HS; Jones RN Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570 [TBL] [Abstract][Full Text] [Related]
12. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents]. Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259 [TBL] [Abstract][Full Text] [Related]
13. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Ueda Y; Sunagawa M Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci. Tünger A; Aydemir S; Uluer S; Cilli F Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141 [TBL] [Abstract][Full Text] [Related]
16. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010). Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693 [TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus]. Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009. Dowzicky MJ Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154 [TBL] [Abstract][Full Text] [Related]
20. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]